Skip to main content
SpringerLink
Log in

Intravenous Ibandronate

In the Treatment of Osteoporosis

  • Adis Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Ibandronate (ibandronic acid) is a potent nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption in women with postmenopausal osteoporosis. Recently, an intravenous (IV) formulation of ibandronate for intermittent injection, which circumvents the fasting and posture requirements associated with administration of oral bisphosphonates, was approved for use in this patient population.

  • ▴ In initial placebo-controlled studies of 1 year's duration, IV ibandronate (≤2mg once every 3 months) increased lumbar spine bone mineral density (BMD) and reduced levels of biochemical markers of bone turnover in a dose-dependent manner. Dosages ≤1mg every 3 months were found to be suboptimal in terms of fracture prevention in a 3-year trial.

  • ▴ Subsequently, the large randomised, double-blind, noninferiority DIVA trial showed that, in terms of increasing lumbar spine BMD (primary endpoint), IV ibandronate 3mg once every 3 months and 2mg once every 2 months for 1 year were noninferior and also superior to oral ibandronate 2.5mg once daily, a regimen with proven antifracture efficacy. Median reductions from baseline in biochemical markers of bone turnover were similar for the IV and oral regimens.

  • ▴ IV ibandronate was generally well tolerated in clinical trials. Treatment-related adverse events included musculoskeletal events and transient influenza-like symptoms, the latter mainly associated with the first dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Scottish Intercollegiate Guidelines Network. Management of osteoporosis: a national clinical guideline. June 2003 (updated Apr 2004) [online]. Available from URL: http://www.sign.ac.uk [Accessed 2006 Jun 12]

  2. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006; 13(3): 340–67

    Article  Google Scholar 

  3. Cranney A. Treatment of postmenopausal osteoporosis: choice of treatment depends on efficacy, individual risk profile, and side effects. BMJ 2003; 327: 355–6

    Article  PubMed  CAS  Google Scholar 

  4. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19(8): 1241–9

    Article  CAS  Google Scholar 

  5. Roche Products Limited. Bonviva 150mg film-coated tablets: summary of product characteristics (EC) [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2006 Jun 12]

  6. Roche Products Limited. Bonviva 3mg/3ml solution for injection in pre-filled syringe: summary of product characteristics (EC) [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2006 Apr 26]

  7. Chapurlat RD. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. Treat Endocrinol 2005; 4(2): 115–25

    Article  PubMed  CAS  Google Scholar 

  8. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004 Jun; 15(6): 423–33

    Article  PubMed  CAS  Google Scholar 

  9. Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997 Oct; 103(4): 298–307

    Article  PubMed  CAS  Google Scholar 

  10. Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004 May; 34(5): 881–9

    Article  PubMed  CAS  Google Scholar 

  11. Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003 Oct; 62(10): 969–75

    Article  PubMed  CAS  Google Scholar 

  12. Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004 Sep; 44(9): 951–65

    Article  PubMed  CAS  Google Scholar 

  13. Delmas PD, Adami S, Strugala CSJA, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis. Arthritis Rheum 2006; 54(6): 1838–46

    Article  PubMed  CAS  Google Scholar 

  14. Recker R, Stakkestad JA, Chesnut CH, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004 May; 34(5): 890–9

    Article  PubMed  CAS  Google Scholar 

  15. Emkey R, Zaidi M, Lewiecki EM, et al. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study [abstract no. L8 plus poster]. 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals: Late Breakers; 2005 Nov 12–17; San Diego (CA)

  16. Delmas PD, Recker RR, Chesnut CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004 Oct; 15(10): 792–8

    Article  PubMed  CAS  Google Scholar 

  17. Data on file. F. Hoffman-La Roche Ltd, Basel, 2006

  18. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000 Jan; 85(1): 231–6

    Article  PubMed  CAS  Google Scholar 

  19. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002 Apr; 87(4): 1586–92

    Article  PubMed  CAS  Google Scholar 

  20. Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003 Oct; 14(10): 801–7

    Article  PubMed  CAS  Google Scholar 

  21. Ringe JD, Dorst A, Faber H. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. Osteoporos Int 2005 Dec; 16(12): 2063–8

    Article  PubMed  CAS  Google Scholar 

  22. Roche Laboratories Inc. Boniva® (ibandronate sodium) injection: package insert (US). [online]. Available from URL: http://www.rocheusa.com [Accessed 2006 Jul 25]

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Katherine F. Croom & Lesley J. Scott

Authors
  1. Katherine F. Croom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine F. Croom.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Croom, K.F., Scott, L.J. Intravenous Ibandronate. Drugs 66, 1593–1601 (2006). https://doi.org/10.2165/00003495-200666120-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666120-00005

Keywords

Search

Navigation